Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Open-Label Study of Zanubrutinib (BGB-3111) Plus Rituximab Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Next Previous
Trial Profile

A Phase 3 Randomized, Open-Label Study of Zanubrutinib (BGB-3111) Plus Rituximab Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Zanubrutinib (Primary) ; Lenalidomide; Obinutuzumab
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms MAHOGANY
  • Sponsors BeOne Medicines

Most Recent Events

  • 18 Apr 2025 Planned number of patients changed from 750 to 780.
  • 27 Feb 2025 According to a BeiGene media release, company anticipate completing enrollment for the relapsed/refractory (R/R) follicular lymphoma portion of the Phase 3 MAHOGANY study in the second half of 2025.
  • 12 Mar 2024 Planned End Date changed from 1 Jun 2029 to 1 Jun 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top